Comparative Efficacy of Low Dose vs High Dose Sildenafil in Treatment of Pulmonary Hypertension in Neonates
DOI:
https://doi.org/10.70749/ijbr.v3i6.2310Keywords:
Persistent Pulmonary Hypertension of the Newborn (PPHN), sildenafil, neonates, low-dose, high-dose, oxygen saturation, echocardiography, adverse effects.Abstract
Background: Persistent Pulmonary Hypertension of the Newborn (PPHN) is a life-threatening condition caused by increased pulmonary vascular resistance, leading to right-to-left shunting of blood and severe hypoxemia. Objective: To compare the efficacy of low dose sildenafil with that of high dose in treatment of PPHN. Methods: This experimental study was conducted at the Neonatology Department of the Children’s Hospital and University of Child Health Sciences, Lahore. 60 neonates diagnosed with PPHN within the first week of life were enrolled. Patients were administered sildenafil orally, starting at 0.5 mg/kg every six hours. The dose was gradually titrated to 2 mg/kg based on oxygen saturation and clinical stability. Key outcomes included improvements in oxygen saturation, echocardiographic measures, and the incidence of adverse effects. Results: Sildenafil treatment significantly improved oxygen saturation in neonates with pulmonary hypertension. The Wilcoxon Signed-Rank Test showed a statistically significant increase in oxygen saturation after treatment. A Mann-Whitney U Test comparing low-dose (0.5 mg/kg) and high-dose (2 mg/kg) groups revealed no significant difference in post-treatment oxygen saturation (p = 1.000). The Spearman’s Rank Correlation test confirmed no correlation between sildenafil dose and oxygen saturation before (ρ = 0.000, p = 1.000) or after treatment (ρ = 0.000, p = 1.000). Additionally, a Chi-Square test found no significant relationship between sildenafil dose and side effects such as hypotension, hypokalemia, anemia, or bradycardia, with all p-values greater than 0.05. Conclusion: Sildenafil effectively increases oxygen saturation in neonates with pulmonary hypertension. Results indicate that increasing sildenafil dose does not provide additional benefits in oxygen saturation or in reducing side effects, supporting the use of lower doses in clinical practice.
Downloads
References
1. Mandell E, Kinsella JP, Abman SH. Persistent pulmonary hypertension of the newborn. Pediatr Pulmonol. 2021;56(3):661-9. PMID: 32930508.
https://doi.org/10.1002/ppul.25073.
2. Fernandez MAY, Gunawijaya E, Yantie NPVK, Sukmawati M. Incidence and outcomes of persistent pulmonary hypertension of the newborn in a tertiary referral center, Indonesia. Intisari Sains Medis. 2023;14(2):482-6.
https://doi.org/10.15562/ism.v14i2.1732
3. Abbas G, Shah S, Hanif M, Shah A, Rehman Au, Tahir S, et al. The frequency of pulmonary hypertension in newborn with intrauterine growth restriction. Sci. Rep. 2020;10(1):8064.
https://doi.org/10.1038/s41598-020-65065-2
4. Nakwan N, Jain S, Kumar K, Hosono S, Hammoud M, Elsayed YY, et al. An Asian multicenter retrospective study on persistent pulmonary hypertension of the newborn: incidence, etiology, diagnosis, treatment and outcome. J Matern Fetal Neonatal Med. 2020;33(12):2032-7.
https://doi.org/10.1080/14767058.2018.1536740
5. Constantine A, Dimopoulos K, Haworth SG, Muthurangu V, Moledina S. Twenty-year experience and outcomes in a National Pediatric Pulmonary Hypertension Service. American Journal of Respiratory and Critical Care Medicine. 2022 Sep 15;206(6):758-66.
https://doi.org/10.1164/rccm.202110-2428OC
6. Hoeper MM, Ewert R, Jansa P, Sirenko Y, Skride A, Balagtas C, et al. Randomized, Multicenter Study to Assess the Effects of Different Doses of Sildenafil on Mortality in Adults With Pulmonary Arterial Hypertension. Circ. 2024;149(25):1949-59.
https://doi.org/10.1161/CIRCULATIONAHA.123.068107
7. He Z, Zhu S, Zhou K, Jin Y, He L, Xu W, et al. Sildenafil for pulmonary hypertension in neonates: An updated systematic review and meta-analysis. 2021;56(8):2399-412.
https://doi.org/10.1002/ppul.25444
8. Kelly LE, Ohlsson A, Shah PS. Sildenafil for pulmonary hypertension in neonates. The Cochrane database of systematic reviews. 2017;8(8):Cd005494.
https://doi.org/10.1002/14651858.CD005494.
9. Sun L, Wang C, Zhou Y, Sun W, Wang C. Clinical efficacy and safety of different doses of sildenafil in the treatment of persistent pulmonary hypertension of the newborn: a network meta-analysis. Frontiers in Pharmacology. 2021;12:697287. https://doi.org/10.3389/fphar.2021.697287
10. Schroeder L, Monno P, Strizek B, Dresbach T, Mueller A, Kipfmueller F. Intravenous sildenafil for treatment of early pulmonary hypertension in preterm infants. Scientific reports. 2023 May 24;13(1):8405.
https://doi.org/10.1038/s41598-023-35387-y
11. Chetan C, Suryawanshi P, Patnaik S, Soni NB, Rath C, Pareek P, et al. Oral versus intravenous sildenafil for pulmonary hypertension in neonates: a randomized trial. BMC Pediatrics. 2022;22(1):311.
https://doi.org/10.1186/s12887-022-03366-3
12. Zhang Q, Xu B, Lv J, Wang Z, Du J. Safety and effect of sildenafil on treating paediatric pulmonary arterial hypertension: a meta-analysis on the randomised controlled trials. Cardiology in the Young. 2020;30(12):1882-9.
https://doi.org/10.1017/S104795112000311X
13. Dabour SA, Asser EH, Hamed A. Risk Factors and Outcomes of Early Pulmonary Hypertension in Preterm Neonate. Benha Journal of Applied Sciences. 2021 Apr 1;6(2):219-25.
https://doi.org/10.21608/bjas.2021.169164
14. Hopper RK, Abman SH, Elia EG, Avitabile CM, Yung D, Mullen MP, Austin ED, Bates A, Handler SS, Feinstein JA, Ivy DD. Pulmonary hypertension in children with Down syndrome: results from the Pediatric Pulmonary Hypertension Network Registry. The Journal of pediatrics. 2023 Jan 1;252:131-40.
https://doi.org/10.1016/j.jpeds.2022.08.027
15. Tao L, Zhou YZ, Shen X. Seasonal variation in urinary PAH metabolite levels and associations with neonatal birth outcomes. Environmental Science and Pollution Research. 2024 Jun;31(29):41893-904.
https://doi.org/10.1007/s11356-024-33888-5
16. Imam SS, El-Farrash RA, Taha AS, Saleh GA. Milrinone versus sildenafil in treatment of neonatal persistent pulmonary hypertension: a randomized control trial. Journal of Cardiovascular Pharmacology. 2022 Nov 1;80(5):746-52.
https://doi.org/10.1097/FJC.0000000000001332
17. Evers PD, Critser PJ, Cash M, Magness M, Hoelle S, Hirsch R. Cost-utility of sildenafil for persistent pulmonary hypertension of the newborn. American journal of perinatology. 2021 Dec;38(14):1505-12.
https://doi.org/10.1055/s-0040-1713819
18. Pierce CM, Zhang MH, Jonsson B, Iorga D, Cheruvu N, Balagtas CC, Steinhorn RH. Efficacy and safety of IV sildenafil in the treatment of newborn infants with, or at risk of, persistent pulmonary hypertension of the newborn (PPHN): a multicenter, randomized, placebo-controlled trial. The Journal of pediatrics. 2021 Oct 1;237:154-61.
https://doi.org/10.1016/j.jpeds.2021.05.051
19. Jackson W, Gonzalez D, Smith PB, Ambalavanan N, Atz AM, Sokol GM, Hornik CD, Stewart D, Mundakel G, Poindexter BB, Ahlfeld SK. Safety of sildenafil in extremely premature infants: a phase I trial. Journal of Perinatology. 2022 Jan;42(1):31-6.
https://doi.org/10.1038/s41372-021-01261-w
20. Hirata K, Nakahari A, Takeoka M, Watanabe M, Nishimura Y, Katayama Y, Isayama T, Japan Evidence Based Neonatology (JEBNeo). Prophylactic sildenafil to prevent bronchopulmonary dysplasia: A systematic review and meta‐analysis. Pediatrics International. 2024 Jan;66(1):e15749.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Indus Journal of Bioscience Research
This work is licensed under a Creative Commons Attribution 4.0 International License.
